Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MYD88 L265P

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MYD88 overexpression (2)

MYD88 overexpression (2)

›

MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
MYD88 L265P	Lymphoma	MYD88 L265P	Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYD88 L265P	Marginal Zone Lymphoma	MYD88 L265P	Marginal Zone Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
MYD88 L265P	Diffuse Large B Cell Lymphoma	MYD88 L265P	Diffuse Large B Cell Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	mavorixafor Sensitive: C3 – Early Trials mavorixafor Sensitive : C3	mavorixafor Sensitive: C3 – Early Trials mavorixafor Sensitive : C3
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
MYD88 L265P	Non-Hodgkin’s Lymphoma	MYD88 L265P	Non-Hodgkin’s Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
MYD88 L265P	Diffuse Large B Cell Lymphoma	MYD88 L265P	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYD88 L265P	Multiple Myeloma	MYD88 L265P	Multiple Myeloma	lenalidomide + bortezomib Sensitive: C4 – Case Studies lenalidomide + bortezomib Sensitive : C4	lenalidomide + bortezomib Sensitive: C4 – Case Studies lenalidomide + bortezomib Sensitive : C4